Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Unrestrained receptor tyrosine kinase (RTK) signaling and epigenetic deregulation are root causes of tumorigenesis. We establish linkage between these processes by demonstrating that aberrant RTK signaling unleashed by oncogenic HRas(G12V) or loss of negative feedback through Sprouty gene deletion remodels histone modifications associated with active typical and super-enhancers. However, although both lesions disrupt the Ras-Erk axis, the expression programs, enhancer signatures, and transcription factor networks modulated upon HRas(G12V) transformation or Sprouty deletion are largely distinct. Oncogenic HRas(G12V) elevates histone 3 lysine 27 acetylation (H3K27ac) levels at enhancers near the transcription factor Gata4 and the kinase Prkcb, as well as their expression levels. We show that Gata4 is necessary for the aberrant gene expression and H3K27ac marking at enhancers, and Prkcb is required for the oncogenic effects of HRas(G12V)-driven cells. Taken together, our findings demonstrate that dynamic reprogramming of the cellular enhancer landscape is a major effect of oncogenic RTK signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 6×
“ChIP-seq analyses were performed as described previously (Loven et al., 2013).”
InfluentialSelf-citationRegulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487 · cited 1×
“Significant enrichment of binding sites for TFs such as TWIST1 (p 0.01) was detected upon HRasG12V-transformation, consistent with the known role of oncogenic Ras in regulating and cooperating with Twist1 in oncogenesis (De Craene and Berx, 2013).”
InfluentialA unique chromatin signature uncovers early developmental enhancers in humans
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011) · Nature · doi:10.1038/nature09692 · Cited by 2,233
Transcription factors: from enhancer binding to developmental control
Spitz, F., & Furlong, E. E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3207 · Cited by 2,227 · cited 1×
“Enhancers contain binding sites for sequence-specific transcription factors (TFs) and associated cofactors that assemble in a combinatorial manner to promote cell-type specific gene expression patterns (Spitz and Furlong, 2012).”
Latent Enhancers Activated by Stimulation in Differentiated Cells
Ostuni, R., Piccolo, V., Barozzi, I., Polletti, S., Termanini, A., Bonifacio, S., Curina, A., Prosperini, E., Ghisletti, S., & Natoli, G. (2013) · Cell · doi:10.1016/j.cell.2012.12.018 · Cited by 867 · cited 3×
“The deposition of H3K4me1 by MLL2 and MLL3, and H3K27ac by p300 and CBP, is dynamically regulated (Brown et al., 2014; Herz et al., 2012; Kaikkonen et al., 2013; Ostuni et al., 2013; Tie et al., 2009).”
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 3×
“therapies targeting cancers driven by oncogenic Ras, the study of this oncogene has become a centerpiece of new basic and translational research efforts (Stephen et al., 2014).”
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735 · cited 2×
“H3K27ac enhancer signatures are useful in the identification of aberrant oncogenic transcriptional programs and classification of malignant tissue (Chapuy et al., 2013).”
Self-citationKaikkonen, M. U., Spann, N. J., Heinz, S., Romanoski, C. E., Allison, K. A., Stender, J. D., Chun, H. B., Tough, D. F., Prinjha, R. K., Benner, C., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.07.010 · Cited by 672 · cited 2×
“The deposition of H3K4me1 by MLL2 and MLL3, and H3K27ac by p300 and CBP, is dynamically regulated (Brown et al., 2014; Herz et al., 2012; Kaikkonen et al., 2013; Ostuni et al., 2013; Tie et al., 2009).”
Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., Crump, N. T., Hazzalin, C. A., Liszczak, G., Yuan, H., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.006 · Cited by 666 · cited 3×
“In addition, treatment of Spry124−/− MEFs with the p300/CBP inhibitor, C646 (Bowers et al., 2010), significantly reduced the expression of 4 out of 7 Spry124−/− target genes tested upon serum deprivation, and significantly diminished FGF-mediated gene activation to Spry124fl/fl levels (Figure S3B).”
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.024 · Cited by 614 · cited 3×
“The deposition of H3K4me1 by MLL2 and MLL3, and H3K27ac by p300 and CBP, is dynamically regulated (Brown et al., 2014; Herz et al., 2012; Kaikkonen et al., 2013; Ostuni et al., 2013; Tie et al., 2009).”
Self-citation
Cited by
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
Self-citationThe dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118
Self-citationSuper-Enhancer-Driven Transcriptional Dependencies in Cancer
Sengupta, S., & George, R. E. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.03.006 · Cited by 351
Arechederra, M., Daian, F., Yim, A., Bazai, S. K., Richelme, S., Dono, R., Saurin, A. J., Habermann, B. H., & Maina, F. (2018) · Nature Communications · doi:10.1038/s41467-018-05550-5 · Cited by 221
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Chromatin dependencies in cancer and inflammation
Marazzi, I., Greenbaum, B. D., Low, D. H. P., & Guccione, E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.113 · Cited by 80
CDK19 is a Regulator of Triple-Negative Breast Cancer Growth
Hsieh, R. W., Kuo, A. H., Scheeren, F. A., Zarnegar, M. A., Sikandar, S. S., Antony, J., Heitink, L. S., Periyakoil, D., Kalisky, T., Sim, S., et al. (2018) · doi:10.1101/317776 · Cited by 3
Metadata
- Authors
- Nabet, B., Ó Broin, P., Reyes, J. M., Shieh, K., Lin, C. Y., Will, C. M., Popovic, R., Ezponda, T., Bradner, J. E., Golden, A. A., & Licht, J. D.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 12
- Issue
- 8
- Pages
- 1300-1313
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W1920455166
- Cited by
- 46
- References
- 14
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.